Invention Application
- Patent Title: REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA
-
Application No.: US18605319Application Date: 2024-03-14
-
Publication No.: US20240415851A1Publication Date: 2024-12-19
- Inventor: Julian SOLWAY , Nickolai DULIN , Marsha ROSNER , Gokhan MUTLU , Diane LUCI , David MALONEY , Chan Young PARK , Jeffrey FREDBERG , David MCCORMICK , Ramaswamy KRISHNAN
- Applicant: The University of Chicago , The United States of America, as Represented by the Secretary, Department of Health and Human , President and Fellows of Harvard College , IIT Research Institute , Beth Israel Deaconess Medical Center, Inc.
- Applicant Address: US IL Chicago; US MD Bethesda; US MA Cambridge; US IL Chicago; US MA Boston
- Assignee: The University of Chicago,The United States of America, as Represented by the Secretary, Department of Health and Human,President and Fellows of Harvard College,IIT Research Institute,Beth Israel Deaconess Medical Center, Inc.
- Current Assignee: The University of Chicago,The United States of America, as Represented by the Secretary, Department of Health and Human,President and Fellows of Harvard College,IIT Research Institute,Beth Israel Deaconess Medical Center, Inc.
- Current Assignee Address: US IL Chicago; US MD Bethesda; US MA Cambridge; US IL Chicago; US MA Boston
- Main IPC: A61K31/635
- IPC: A61K31/635 ; A61K31/18 ; A61K31/63 ; A61P35/04 ; C07C311/16 ; C07C311/21 ; C07D207/48 ; C07D211/34 ; C07D211/96 ; C07D239/42 ; C07D241/04 ; C07D265/30 ; C07D277/52 ; C07D279/12 ; C07D295/13 ; C07D295/26 ; C07D309/14 ; C07D401/12 ; C07D471/04 ; C07D487/08 ; C07D491/113
Abstract:
Disclosed herein is a class of molecules termed remodilins that inhibit serum response factor (SRF). By inhibiting SRF, a number of downstream pathways can be targeted. The remodilins can be used to treat glaucoma, inhibit tumor cell growth, inhibit tumor metastasis, inhibit hypoxia-induced response, and/or reduce cellular metabolism.
Information query
